AACR 2023 Conference Coverage
A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resected HR-Melanoma: Efficacy & Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial
By
AACR 2023 Conference Coverage
FEATURING
Jeffrey Weber
By
AACR 2023 Conference Coverage
FEATURING
Jeffrey Weber
Comments 0
Login to view comments.
Click here to Login
